Journal of Molecular and Cellular Cardiology
Volume 43, Issue 2 , Pages 130-136 , August 2007

Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia–reperfusion

Received 1 April 2007 ,Revised 25 April 2007 ,Accepted 14 May 2007.

References 

  1. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89(1):151–163
  2. Zimmerman SD, Criscione J, Covell JW. Remodelling in the myocardium adjacent to an infarction in a pig left ventricle. Am. J. Physiol. 2004;287:H2697–H2704
  3. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J. Am. Coll. Cardiol. 2004;44(2):276–286
  4. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293(1):90–95
  5. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia–reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 2003;100(8):4802–4806
  6. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003;112(7):999–1007
  7. Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, et al. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 2007;120:163–70.
  8. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64(5):1648–1652
  9. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res. 2005;65:719–727
  10. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS. 2003;100(20):11612–11617
  11. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 2006;101(1):31–39
  12. Gao E, Boucher M, Chuprun JK, Zhou R, Eckhart A, Koch WJ. Darbepoetin alpha, a long-acting erythropoietin analogue, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol (in press).
  13. Kritensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, et al. Lack of acute cardioprotective effect from preischemic erythropoietin administration in a porcine coronary occlusion model. Clin. Physiol. Funct. Imaging. 2005;25:305–310
  14. Olea FD, Vera Janavel G, De Lorenzi A, Cuniberti L, Yannarelli G, Cabeza Meckert P, et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J. Cardiovasc. Pharmacol. 2006;47:736–741
  15. Dohi K, Pinsky MR, Kanzaki H, Severyn D, Gorcsan J. Effects of radial left ventricular dyssynchrony on cardiac performance using quantitative tissue Doppler radial strain imaging. J. Am. Soc. Echocardiogr. 2006;19(5):475–482
  16. Matre K, Fannelop T, Dahle GO, Heimdal A, Grong K. Radial strain gradient across the normal myocardial wall in open-chest pigs measured with Doppler strain rate imaging. J. Am. Soc. Echocardiogr. 2005;18(10):1066–1073
  17. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006;48(1):176–184
  18. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 2006;20(2):135–141
  19. Krause KT, Jaquet K, Geidel S, Schneider C, Mandel C, Stoll HP, et al. Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur. J. Heart Fail. 2006;8(5):443–450
  20. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation. 2006;113(4):535–543
  21. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 2004;279(20):20655–20662
  22. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002;64(2):326–333
  23. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106(23):2973–2979
  24. Van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005 (Jul 5);46(1):125–133
  25. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 2003 (May 30);92(10):1098–1106
  26. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006 (Mar 1);107(5):1892–1895
  27. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, et al. Expression of the erythropoietin receptor in the human heart. J. Thorac. Cardiovasc. Surg. 2005;130(3):877–878
  28. Weidemann F, Jamal F, Kowalski M, Kukulski T, D'Hooge J, Bijnens B, et al. Can strain rate and strain quantify changes in regional systolic function during dobutamine infusion, B-blockade, and atrial pacing-implications for quantitative stress echocardiography. J. Am. Soc. Echocardiogr. 2002;15(5):416–424
  29. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time?. J. Am. Coll. Cardiol. 2006;47(7):1313–1327

PII: S0022-2828(07)01053-X

doi: 10.1016/j.yjmcc.2007.05.014

Journal of Molecular and Cellular Cardiology
Volume 43, Issue 2 , Pages 130-136 , August 2007

Article Tools

* Image Usage & Resolution